For more information visit Forward-Looking Statements : HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.īuilding on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. “I look forward to the opportunity to share the power of this drug discovery engine with potential partners and customers at the BIO International Convention and to continue to help others see how our technology can be used to make more well-informed selection choices earlier in the drug discovery process and improve the chances for success in development when compared to existing drug discovery and development approaches.” Further, the data that our team has generated in these studies serve as a tangible demonstration of the power of the drug discovery engine we have built,” said Dr. “We have demonstrated that our innovative approach to drug discovery allows for the progression of molecules from target to drug candidate in approximately 12 months, with the added benefit of developing much deeper knowledge about the biological responses in diseased cells at earlier stages in discovery. Meetings with the company’s management team to discuss opportunities to partner on existing portfolio molecules or to use HTG’s platform to support potential partner company pipelines can be requested by conference participants through the BIO International Conference website. Barat and HTG’s Chief Executive Officer, John Lubniewski, will also be available for in-person meetings throughout the conference. Barat, Ph.D., will present the benefits of the company’s innovative approach to drug discovery as well as data from the company’s lead molecules demonstrating the utility of the platform to attendees of the BIO International Convention on Tuesday, June 6, 2023 at 2:15 PM Eastern. The company’s Senior Vice President of Therapeutics, Stephen A. The company’s most advanced discovery programs are in oncology with an emphasis on the treatment of acute myeloid leukemia (AML), with the first molecules currently progressing through the remaining portion of lead optimization and expected to have sufficient data to support entry into preclinical development in the third quarter of 2023. At the center of this approach is HTG’s proprietary RNA profiling technologies, functionally married with an advanced medicinal chemistry using a novel artificial intelligence (AI)-driven platform, allowing for the improved selection and design of molecules. HTG’s objective is to develop best-in-class molecules for the treatment of diseases, with the ability to apply its platform agnostically across therapy areas. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. H HTGM (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA. If you choose to do business with this business, please let the business know that you contacted BBB for a BBB Business Profile.Īs a matter of policy, BBB does not endorse any product, service or business.TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) - HTG Molecular Diagnostics, Inc. BBB Business Profiles are subject to change at any time. When considering complaint information, please take into account the company's size and volume of transactions, and understand that the nature of complaints and a firm's responses to them are often more important than the number of complaints.īBB Business Profiles generally cover a three-year reporting period. However, BBB does not verify the accuracy of information provided by third parties, and does not guarantee the accuracy of any information in Business Profiles. BBB asks third parties who publish complaints, reviews and/or responses on this website to affirm that the information provided is accurate. BBB Business Profiles may not be reproduced for sales or promotional purposes.īBB Business Profiles are provided solely to assist you in exercising your own best judgment.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |